Provided by Tiger Trade Technology Pte. Ltd.

First Trust Nasdaq Pharmaceuticals ETF

40.73
-0.0900-0.22%
Post-market: 40.730.00000.00%19:30 EDT
Volume:53.73K
Turnover:2.19M
Market Cap:1.04B
PE:- -
High:40.88
Open:40.82
Low:40.53
Close:40.82
52wk High:43.52
52wk Low:28.77
Shares:25.65M
Float Shares:25.65M
Volume Ratio:0.06
T/O Rate:0.21%
Dividend:0.29
Dividend Rate:0.71%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Moderna Stock Has Run Too Far, Too Fast. Why Citi Just Downgraded it to Sell

Dow Jones
·
Sep 30

Kenvue Says Post-Hoc Phase III Analysis Links Earlier 5% Minoxidil Use to Higher Hair Regrowth in Men with Androgenetic Alopecia

Reuters
·
Sep 30

Marka S.A. Pays Twelfth Installment Under Amended Bondholder Arrangement

TIPRANKS
·
Sep 30

Johnson & Johnson Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Benzinga Earnings
·
Sep 30

AbbVie reports ‘positive’ results from Phase 2 APEX Part B study of zumilokibart

TIPRANKS
·
Sep 30

AbbVie Starts Phase 2 Obesity Trial of Gubra-Discovered Amylin Analog ABBV-295

Reuters
·
Sep 30

Abbvie: in Phase 1 Abbv-295 Study, All Dosing Regimens Resulted in Ls Mean Weight Loss up to About 10% over 3-Month Treatment Period

THOMSON REUTERS
·
Sep 30

Abbvie: 82.2% of All Abbv-295 Treated Participants Reported Mild Adverse Events as Highest Reported Ae Severity

THOMSON REUTERS
·
Sep 30

AbbVie Says Phase 1 ABBV-295 Study Shows Mean Weight Loss up to About 10% over 3-Month Period

Reuters
·
Sep 30

AbbVie Says Mid-Stage Study of Atopic Dermatitis Treatment Meets Primary Goal

MT Newswires Live
·
Sep 30

Abbvie Highlights Positive Results from the Phase 2 Apex Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at Eadv 2026

THOMSON REUTERS
·
Sep 30

AbbVie Presents Phase 2 APEX Part B Data for Zumilokibart in Moderate-to-Severe Atopic Dermatitis at EADV 2026

Reuters
·
Sep 30

Eli Lilly reports results from TRIUMPH-2 Phase 3 trial

TIPRANKS
·
Sep 30

Lilly's Experimental Drug Cuts Weight by 21% in Diabetes Trial

Reuters
·
Sep 30

Eli Lilly - Retatrutide 12 Mg Results in 49.6 Lb (20.8%) Weight Loss over 80 Weeks

THOMSON REUTERS
·
Sep 30

Lilly's Triple Agonist, Retatrutide, Delivered Substantial Weight Loss and A1c Reduction, Underscoring Its Potential Promise for People with Obesity and Type 2 Diabetes

THOMSON REUTERS
·
Sep 30

Eli Lilly - to Submit Biologics License Application for Retatrutide in Q1 2027

THOMSON REUTERS
·
Sep 30

Eli Lilly - 59.5% of Retatrutide 12 Mg Participants no Longer Meet Bmi Criteria for Obesity

THOMSON REUTERS
·
Sep 30

AbbVie Inc. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Sep 30

Johnson: AI Providers Committed to Building Trust

THOMSON REUTERS
·
Sep 30